EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AP2M1 Amplification Orchestrates Notch‐Mediated Chemoresistance in Hematopoietic Stem Cells of Acute Myeloid Leukemia Patients

Hansong Lee, Eun Kyoung Kim, Hee Young Ju, Chae Rin Lee, Soyul Ahn, Eun-Sun Kim, Kyungjae Myung, Won Kyu Kim, Su-Yeon Cho, Yujin Kwon, Dokyoung Kim, Yeuni Yu und 17 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202514566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Hansong Lee und 28 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Institute, Pusan National University, Yangsan, 50612, Republic of Korea. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Drug Resistance, Neoplasm, Hematopoietic Stem Cells, Adaptor Protein Complex 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Samsung Medical Center BioBank, Daewoong Foundation, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by chemotherapy resistance, leading to poor patient outcomes. This study investigates the role of adaptor protein complex 2 subunit mu 1 (AP2M1) in hematopoiesis and drug response. Utilizing multimodal analyses on bone marrow samples from AML patients and healthy controls, zebrafish models, and human AML cell lines, it is identified that dysregulation of AP2M1 impairs hematopoietic stem and progenitor cell (HSPC) development, underscoring its critical role in hematopoiesis. AP2M1 expression distinctly differentiates normal from malignant cells, surpassing well‐recognized cancer stem cell markers, ATP‐binding cassette transporters, known for drug efflux and chemoresistance. Elevated AP2M1 levels in AML HSPCs correlate with poor clinical outcomes, as its overexpression reduces apoptosis, enhances stemness, and increases drug resistance. In vivo experiments reveal that AP2M1 directly modulates Notch1 expression, amplifying pro‐tumorigenic effects through the Notch1 signaling pathway. These findings highlight the pivotal role of AP2M1 in AML pathogenesis, primarily through its regulation of NOTCH1 expression and signaling cascades. These findings unravel AP2M1 as a previously unrecognized factor in AML pathogenesis and suggest a treatment strategy for AML, focusing on the AP2M1‐NOTCH1 axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteDrug Resistance, NeoplasmHematopoietic Stem CellsAdaptor Protein Complex 2Receptor, Notch1HumansAnimalsZebrafishSignal TransductionCell Line, TumorFemaleNeoplastic Stem CellsMale

Stichwörter der Autor:innen

AMLAP2M1HSPCNOTCHchemoresistance

Substanzen

Adaptor Protein Complex 2Receptor, Notch1NOTCH1 protein, human

Autor:innen und Institutionen

  • Medical Research Institute, Pusan National University, Yangsan, 50612, Republic of Korea.
  • Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, School of Medicine, Core Research Institute (CRI), Kyung Hee University, Seoul, 02447, Republic of Korea.
  • Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Republic of Korea.
  • Department of Convergence Medical Sciences, School of Medicine, Pusan National University, Yangsan, 50612, Republic of Korea.
  • Center for Genomic Integrity, Institute for Basic Science (IBS), Ulsan, 44919, Republic of Korea.
  • Center for Natural Product Efficacy Optimization, Korea Institute of Science and Technology (KIST), Gangneung, 25451, Republic of Korea.

ORCID-Profile: Yun Hak Kim

Förderung

  • Samsung Medical Center BioBank
  • Daewoong Foundation
  • National Research Foundation of Korea
  • Korea Research Environment Open Network

Zitieren

APA

Lee, H., Kim, E. K., Ju, H. Y., Lee, C. R., Ahn, S., Kim, E. S., Myung, K., Kim, W. K., Cho, S. Y., Kwon, Y., Kim, D., Yu, Y., Kwon, E. J., Kim, H., Mun, S. I., Lim, D. M., Kim, K., Heo, H. J., Baek, S. E., …, & Kim, Y. H. (2025). AP2M1 Amplification Orchestrates Notch‐Mediated Chemoresistance in Hematopoietic Stem Cells of Acute Myeloid Leukemia Patients. Advanced Science. https://doi.org/10.1002/advs.202514566

Vancouver

Lee H, Kim EK, Ju HY, Lee CR, Ahn S, Kim ES, et al. AP2M1 Amplification Orchestrates Notch‐Mediated Chemoresistance in Hematopoietic Stem Cells of Acute Myeloid Leukemia Patients. Advanced Science. 2025. doi:10.1002/advs.202514566

BibTeX
@article{Lee2025,
  author = {Lee, Hansong and Kim, Eun Kyoung and Ju, Hee Young and Lee, Chae Rin and Ahn, Soyul and Kim, Eun-Sun and Myung, Kyungjae and Kim, Won Kyu and Cho, Su-Yeon and Kwon, Yujin and Kim, Dokyoung and Yu, Yeuni and Kwon, Eun Jung and Kim, Hyomin and Mun, Seong Ik and Lim, Dong Min and Kim, Kihun and Heo, Hye Jin and Baek, Seung Eun and Lee, Sun Young and Cho, Hyunsoo and Choi, Eun Young and Goh, Tae Sik and Baryawno, Ninib and Lee, Dongjun and Jung, Ki Sun and Yoo, Keon Hee and Oh, Chang-Kyu and Kim, Yun Hak},
  title = {AP2M1 Amplification Orchestrates Notch‐Mediated Chemoresistance in Hematopoietic Stem Cells of Acute Myeloid Leukemia Patients},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202514566}
}
Kostenlos starten →